The US Food and Drug Administration has granted breakthrough therapy designation to an EGFR tyrosine kinase inhibitor for the first-line treatment of EGFR-positive non-small cell lung cancer. READ MORE
Research in Review
A study of a new novel vaccine for the treatment of non-small cell lung cancer (NSCLC) may have found potential benefits for specific patients who initiate immunotherapy within 12 weeks of completing chemotherapy and who have received prior radiation. The study was published in the European Journal of Cancer.
Despite guidelines from the Society of Thoracic Surgeons suggesting fewer brain imaging tests, in a study published in Chest, researchers found that 12% of participants with stage IA NSCLC in the National Lung Screening Trial underwent at least one brain-imaging test.
Researchers from the University of Texas-Southwest Medical Center compared the immunotherapy drug nivolumab with a commonly used chemotherapy drug and found that it improved overall survival with minimal adverse side effects for patients with non-squamous non-small cell lung cancer (NSCLC) whose disease continued to progress after first-line chemotherapy.